Their extensive portfolio includes over 5,000 readily available lead antibody molecules designed for approximately 400 drug targets. Each of these molecules comes with verified sequences and validation data. In the coming years, they aim to develop lead antibodies for all potential drug targets, reaffirming our commitment to speeding up antibody-based drug discovery for BioPharma companies through our antibodies and flexible partnership options.

Throughout their journey, they’ve been dedicated to innovating and optimizing various technologies for antibody-based drug development. Here’s a brief overview of their cutting-edge platforms:

• DiMPro™ Membrane Protein Platform: 

  This company specializes in expressing and purifying membrane proteins using mammalian cells. Our extensive inventory comprises over 1,000 functional proteins, including 500+ active full-length multi-pass membrane proteins. They offer five distinct solutions for multi-pass transmembrane proteins, such as GPCRs and ion channels: Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent, and Synthetic Nanodisc.

• DimAb® Single B-Cell Antibody Discovery Platform:

  The DimAb® B cell library enables customers to access over 10,000 positive hits in just one month.

• DiLibrary™ Mammalian Display Antibody Engineering Platform: 

  Their proprietary platform excels in antibody humanization, affinity maturation, and other engineering applications. Antibodies engineered through this system demonstrate superior developability compared to those produced by phage or yeast display platforms.

• DiAssay^TMAntibody Evaluation Platform: 

  Dima Biotechnologies offer a range of screening processes to help drug developers identify the ideal hit molecules for their specific antibody drug modalities. They’ve developed three distinct platforms suitable for Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs), and Chimeric Antigen Receptor T-cell Therapies (CAR-T).